Duchenne muscular dystrophy (DMD) cardiomyopathy patients currently have no therapeutic options. We evaluated catheter-based transendocardial delivery of a recombinant adeno-associated virus (rAAV) expressing a small nuclear U7 RNA (U7smOPT) complementary to specific cis-acting splicing signals. Eliminating specific exons restores the open reading frame resulting in translation of truncated dystrophin protein. To test this approach in a clinically relevant DMD model, golden retriever muscular dystrophy (GRMD) dogs received serotype 6 rAAV-U7smOPT via the intracoronary or transendocardial route. Transendocardial injections were administered with an injection-tipped catheter and fluoroscopic guidance using X-ray fused with magnetic resonance imaging (XFM) roadmaps. Three months after treatment, tissues were analyzed for DNA, RNA, dystrophin protein, and histology. Whereas intracoronary delivery did not result in effective transduction, transendocardial injections, XFM guidance, enabled 30±10 non-overlapping injections per animal. Vector DNA was detectable in all samples tested and ranged from <1 to >3000 vector genome copies per cell. RNA analysis, western blot analysis, and immunohistology demonstrated extensive expression of skipped RNA and dystrophin protein in the treated myocardium. Left ventricular function remained unchanged over a 3-month follow-up. These results demonstrated that effective transendocardial delivery of rAAV-U7smOPT was achieved using XFM. This approach restores an open reading frame for dystrophin in affected dogs and has potential clinical utility.
Your institute does not have access to this article
Open Access articles citing this article.
Journal of Cardiovascular Magnetic Resonance Open Access 10 January 2014
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Drousiotou A, Ioannou P, Georgiou T, Mavrikiou E, Christopoulos G, Kyriakides T et al. Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet test 1998; 2: 55–60.
Emery AE . Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul disord 1991; 1: 19–29.
Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50: 509–517.
Hoffman EP, Brown RH, Kunkel LM . Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919–928.
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77–93.
Connuck DM, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008; 155: 998–1005.
Nigro G, Comi LI, Politano L, Bain RJ . The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990; 26: 271–277.
Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat med 2007; 13: 204–210.
Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Bécane HM et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005; 45: 855–857.
De Angelis FG, Sthandier O, Berarducci B, Toso S, Galluzzi G, Ricci E et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc Natl Acad Sci USA 2002; 99: 9456–9461.
Denti MA, Rosa A, D'Antona G, Sthandier O, De Angelis FG, Nicoletti C et al. Chimeric adeno-associated virus/antisense U1 small nuclear RNA effectively rescues dystrophin synthesis and muscle function by local treatment of mdx mice. Hum Gene Ther 2006; 17: 565–574.
Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004; 306: 1796–1799.
Cooper BJ, Winand NJ, Stedman H, Valentine BA, Hoffman EP, Kunkel LM et al. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 1988; 334: 154–156.
Kornegay JN, Tuler SM, Miller DM, Levesque DC . Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 1988; 11: 1056–1064.
Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 1992; 13: 115–121.
Suter D, Tomasini R, Reber U, Gorman L, Kole R, Schümperli D et al. Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations. Hum Mol Genet 1999; 8: 2415–2423.
Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC et al. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 2006; 14: 401–407.
Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G . Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 1998; 7: 1083–1090.
Fletcher S, Ly T, Duff RM, Mc CHJ, Wilton SD . Cryptic splicing involving the splice site mutation in the canine model of Duchenne muscular dystrophy. Neuromuscul Disord 2001; 11: 239–243.
Gorman L, Suter D, Emerick V, Schumperli D, Kole R . Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci USA 1998; 95: 4929–4934.
Wilton SD, Fletcher S . Modification of pre-mRNA processing: application to dystrophin expression. Curr Opin Mol Ther 2006; 8: 130–135.
Popplewell LJ, Adkin C, Arechavala-Gomeza V, Aartsma-Rus A, de Winter CL, Wilton SD et al. Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: implications for future clinical trials. Neuromuscul disord 2010; 20: 102–110.
Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378: 595–605.
Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513–1522.
van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357: 2677–2686.
Barbash IM, Leor J, Feinberg MS, Tessone A, Aboulafia-Etzion S, Orenstein A et al. Interventional magnetic resonance imaging for guiding gene and cell transfer in the heart. Heart 2004; 90: 87–91.
Boekstegers P et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Therapy 2000; 7: 232–240.
Hayase M, Del Monte F, Kawase Y, Macneill BD, McGregor J, Yoneyama R et al. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol 2005; 288: H2995–H3000.
Wright MJ, Wightman LM, Latchman DS, Marber MS . In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo. Gene Therapy 2001; 8: 1833–1839.
Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM et al. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Therapy 2008; 15: 1550–1557.
Bish LT, Sleeper MM, Brainard B, Cole S, Russell N, Withnall E et al. Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther 2008; 16: 1953–1959.
Sanborn TA, Hackett NR, Lee LY, El-Sawy T, Blanco I, Tarazona N et al. Percutaneous endocardial transfer and expression of genes to the myocardium utilizing fluoroscopic guidance. Catheter Cardiovasc Interv 2001; 52: 260–266.
Sylven C, Sarkar N, Insulander P, Kennebäck G, Blomberg P, Islam K et al. Catheter-based transendocardial myocardial gene transfer. J Intervent cardiol 2002; 15: 7–13.
Bish LT, Sleeper MM, Forbes SC, Wang B, Reynolds C, Singletary GE et al. Long-term Restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol Ther 2012; 20: 580–589.
Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P et al. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome 2012; 23: 85–108.
Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ . Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv 2002; 55: 392–397.
Levy HC, Bowman VD, Govindasamy L, McKenna R, Nash K, Warrington K et al. Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol 2009; 165: 146–156.
Shen WY, Lai CM, Lai YK, Zhang D, Zaknich T, Sutanto EN et al. Practical considerations of recombinant adeno-associated virus-mediated gene transfer for treatment of retinal degenerations. J Gene Med 2003; 5: 576–587.
Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105: 539–542.
Cecchini S, Virag T, Kotin RM . Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures. Hum gene ther 2011; 22: 1021–1030.
Naimark WA, Lepore JJ, Klugherz BD, Wang Z, Guy TS, Osman H et al. Adenovirus-catheter compatibility increases gene expression after delivery to porcine myocardium. Hum gene ther 2003; 14: 161–166.
Gutierrez LF, Silva R, Ozturk C, Sonmez M, Stine AM, Raval AN et al. Technology preview: X-ray fused with magnetic resonance during invasive cardiovascular procedures. Catheter Cardiovasc Interv 2007; 70: 773–782.
Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 2003; 12: 907–914.
Cooper ST, Lo HP, North KN . Single section Western blot: improving the molecular diagnosis of the muscular dystrophies. Neurology 2003; 61: 93–97.
We are grateful to the NHLBI Laboratory of Animal Medicine and Surgery technologists for assistance with animal experiments, and the veterinarians and technicians of the Division of Veterinary Research and Victor Wright for assistance with MRI scans. We appreciate the professional skills and advice of the Dr Christian Combs, NHLBI Light Microscopy Core, and Dr Xu-Zi Yu, NHLBI Pathology Core. Dr Victoria Joan Hoffman of Diagnostic & Research Services Branch, Division of Veterinary Resources, NIH, provided essential support and advice. Dr H Lee Sweeney provided helpful comments and discussion. We thank Boston Scientific for providing the injection catheters. Funding was provided by the National Heart, Lung, and Blood Institute, Division of Intramural Research, and the International Collaborative Effort (ICE) for Duchenne Muscular Dystrophy. The ICE consists of the Duchenne Parent Project France and the Association Monagasque Contre les Myopathies.
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on Gene Therapy website
About this article
Cite this article
Barbash, I., Cecchini, S., Faranesh, A. et al. MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Gene Ther 20, 274–282 (2013). https://doi.org/10.1038/gt.2012.38
- Duchenne muscular dystrophy
100-fold but not 50-fold dystrophin overexpression aggravates electrocardiographic defects in the mdx model of Duchenne muscular dystrophy
Molecular Therapy - Methods & Clinical Development (2016)
Journal of Cardiovascular Magnetic Resonance (2014)
Pflügers Archiv - European Journal of Physiology (2014)
Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients
Molecular Therapy (2014)